Vectura’s portfolio has emerged from the Company’s product development, formulation and drug delivery expertise and is currently centred around developing inhaled products to address unmet needs in airways diseases.

We continue to focus on balancing the unmet needs of all stakeholders (patients, physicians, payors) with commercial attractiveness and exploiting valuable niches in our therapeutic space.

   Investors

Date: 12/02/2016

Share price summary

1

WE INNOVATE

2

WE DEVELOP

3

WE COLLABORATE

Annual report

AR-15.png

Download annual report

Presentations and webcasts

09 June 2016

Jefferies 2016 Healthcare Conference, New York

23-24 February 2016

RBC Capital Markets Global Healthcare Conference, New York

11-14 January 2016

J.P. Morgan Annual Healthcare Conference, San Francisco